January 18th 2021
Before New Year’s Day, millions of Americans had received the coronavirus disease 2019 vaccine, including frontline physicians and health care providers and nursing home patients, our most vulnerable citizens.
October 2nd 2017
It can be tough running a community-based oncology practice. Hospitals are expanding their oncology operations, there is a shortage of oncologists—particularly business-minded oncologists—and public and private payers have made it more difficult to get paid.
October 2nd 2017
With cancer being such a difficult disease to understand, treat, and—of course—cure, any knowledge that advances practice is invaluable.
September 28th 2017
It was just 6 years ago that options for patients with metastatic melanoma began to expand. In 2011, the approval of ipilimumab (Yervoy), the pioneering checkpoint immunotherapy for patients with unresectable or metastatic disease, marked the first milestone.
September 20th 2017
Chimeric antigen receptor T-cell therapy may soon hit the market, and numerous cancer care centers are poised to offer this for what may be the first FDA-approved indication: relapsed/refractory B-cell acute lymphoblastic leukemia.
August 17th 2017
The American Urological Association Annual Meeting features stellar research, engaging panel discussions, and informative lectures from experts in the field, but it also offers an opportunity for urologists from around the world to gather.
June 20th 2017
State-of-the-art technology is as valuable in oncology as it is everywhere else. However, new technology is not always available to providers, and when it is, it may not be used to its fullest potential.
June 17th 2017
Although the past few months have seen several androgen receptor resistance, and described drug approvals for bladder cancer therapies, a wealth of research also is moving the field of prostate cancer forward, since gaining a better understanding of the disease is the best way to find out how to optimally treat—and perhaps ultimately cure—prostate cancer.
May 1st 2017
Although there has been much discussion in recent months about the promise of precision medicine to improve outcomes for patients with cancer, the challenges and complexities of reaching that goal become strikingly evident as soon as we start trying to individualize therapies based on molecularly identified targets.
May 1st 2017
The clock is ticking on the anticipated implementation of the US Pharmacopeial Convention Chapter 800 (USP ) standards for hazardous drug management, which are expected to become widely enforceable starting July 1, 2018.
May 1st 2017
In recent years, immunotherapy advancements have generated much excitement in oncology, and that is no different in the urologic arena.
April 28th 2017
Although biosimilar versions of branded medicines have been proliferating in other parts of the world for more than a decade, we’re still getting accustomed to the introduction of these new therapeutic options in the United States.
April 13th 2017
Survivorship care for patients who have had cancer is a relatively new phenomenon in the oncology field. After all, the transformation of many cancers from fatal to chronic conditions has occurred in less than a decade. Not surprisingly, then, the science of survivorship care is still evolving, too.
April 5th 2017
The relentless pace of change in cancer research and care is hardly news to practicing oncologists. It is worthwhile, however, to pause at times and ponder the implications of the speed and complexity of those developments.
April 4th 2017
When it comes to achievements in the war against cancer, there’s much to celebrate, ASCO said in its fourth annual report on the state of cancer care in America, which we discuss in our lead story this month for Oncology Business ManagementTM.
March 28th 2017
One of the most gratifying aspects of the current age of discovery in anticancer therapy is the evolution of once-fatal malignancies into chronic diseases. The pace of progress, however, has not been equal across tumor types.
March 18th 2017
As cancer therapy becomes increasingly high tech, it is often easy to overlook the contributions that individual oncologists make to advancements in the eld simply by being top-notch clinicians who are observant and concerned about their patients.
March 5th 2017
Although the concept of using genetically engineered T cells to fight cancer has been under study for more than 50 years, the most dramatic strides in designing new therapies have come in the past several years.